A61K 51/103
Against receptors for growth factors or receptors for growth regulators
Official title: {against receptors for growth factors or receptors for growth regulators}
A61K51/103 (Against receptors for growth factors or receptors for growth regulators) appears on 63 US grants and 124 published applications in this corpus.
Search patents in A61K- Granted patents
- 63
- Published applications
- 124
- Assignees
- 81
- Inventors
- 317
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 2 |
| 2003 | 0 | 1 |
| 2004 | 1 | 2 |
| 2005 | 1 | 0 |
| 2006 | 1 | 3 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 3 |
| 2010 | 2 | 6 |
| 2011 | 1 | 6 |
| 2012 | 1 | 1 |
| 2013 | 2 | 3 |
| 2014 | 1 | 6 |
| 2015 | 2 | 10 |
| 2016 | 4 | 5 |
| 2017 | 5 | 7 |
| 2018 | 6 | 9 |
| 2019 | 3 | 3 |
| 2020 | 4 | 3 |
| 2021 | 2 | 11 |
| 2022 | 2 | 8 |
| 2023 | 2 | 4 |
| 2024 | 2 | 13 |
| 2025 | 0 | 8 |
| 2026 | 3 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases8 Sep 2026US 12,728,176 B2Actinium Pharmaceuticals, Inc.
- HER3 radioimmunotherapy for the treatment of solid cancers1 Sep 2026US 12,721,915 B2Actinium Pharmaceuticals, Inc.
- Methods for making radiolabeled anti-MET binding proteins21 Apr 2026US 12,605,473 B2Regeneron Pharmaceuticals, Inc.
- Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies26 Nov 2024US 12,151,004 B2University of Saskatchewan
- Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof13 Feb 2024US 11,896,682 B2Regeneron Pharmaceuticals, Inc.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Radiolabeled activated ester and precursor thereof24 Sep 2026US 2026/0284238 A1Institute of Science Tokyo
- Novel anti-gprc5d antibody24 Sep 2026US 2026/0285972 A1Chimagen Biosciences, Ltd.
- Reagents and methods for imaging cancers expressing pdgfralpha20 Aug 2026US 2026/0241050 A1Eli Lilly and Company
- PCTA derivatives, conjugates thereof and uses thereof16 Jul 2026US 2026/0199535 A1Novartis AG
Most cited
By later US patents
- Antibodies specific for type II mutant EGTR84US 5,212,290 ADuke University · 1993
- Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 42547US 5,470,571 AThe Wistar Institute · 1995
- Human anti-epidermal growth factor receptor single-chain antibodies36US 6,699,473 B2The UAB Research Foundation · 2004
- Antibody variants having modifications in the constant region29US 9,085,625 B2Genmab A/S · 2015
- Structural alterations of the EGF receptor gene in human gliomas26US 5,401,828 ADuke University · 1995